As numerous bodies of research have characterized the adipocytokine adiponectin (ACRP30) as an anti-diabetic compound, this work serves as an analysis to partly elucidate the potential usage of supplementary adiponectin as a therapeutic compound in the treatment of type II diabetes mellitus. In this work, a meta-analysis was conducted to centralize large amounts of data on adiponectin’s insulin sensitizing characteristics in conjunction with like-minded studies utilizing metformin treatment as the diabetic standard of care. Upon comparison of fasting glucose, fasting insulin, and glucose tolerance test area under the curve reduction percentages, it is quite clear that ACRP30 has significant insulin enhancing properties in mouse models rivaling SOC metformin. Yet, inconsistent dosing comparisons in this analysis, the unknowns of chronic hyperadiponectinemia in humans, as well as variations in age of human diabetic patients warrant further standardized research to suggest that adiponectin supplementation can rival that of modern-day standard of care for type II diabetes mellitus.
| Identifer | oai:union.ndltd.org:ucf.edu/oai:stars.library.ucf.edu:honorstheses-2285 |
| Date | 01 January 2022 |
| Creators | Romero, Stephen L |
| Publisher | STARS |
| Source Sets | University of Central Florida |
| Language | English |
| Detected Language | English |
| Type | text |
| Format | application/pdf |
| Source | Honors Undergraduate Theses |
Page generated in 0.0013 seconds